Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis.
about
Apremilast in the therapy of moderate-to-severe chronic plaque psoriasisRelationship between Non-Alcoholic Fatty Liver Disease and Psoriasis: A Novel Hepato-Dermal Axis?Nonalcoholic Fatty liver disease and psoriasis: what a dermatologist needs to knowNonalcoholic fatty liver disease - A multisystem disease?Management of moderate to severe psoriasis in patients with metabolic comorbiditiesPsoriasis: classical and emerging comorbiditiesPsoriasis and Atopic Dermatitis.Considerations for Systemic Treatment of Psoriasis in Obese Patients.Efficacy and safety of secukinumab in chronic plaque psoriasis and psoriatic arthritis therapyA subpopulation of CD163-positive macrophages is classically activated in psoriasis.Psoriasis and comorbidities: links and risks.Adiponectin levels in patients with psoriasis: a meta-analysis.Diagnostic accuracy of noninvasive markers of liver fibrosis in patients with psoriasis taking methotrexate: a systematic review and meta-analysis.Non-alcoholic fatty liver disease and psoriasis: So far, so near.The Th17 axis in psoriatic disease: pathogenetic and therapeutic implications.Risk of non-alcoholic fatty liver disease in patients with psoriasis: a systematic review and meta-analysis.Nutrition: a key environmental dietary factor in clinical severity and cardio-metabolic risk in psoriatic male patients evaluated by 7-day food-frequency questionnaire.The Prevalence of Nonalcoholic Fatty Liver Disease and Related Metabolic Comorbidities Was Associated with Age at Onset of Moderate to Severe Plaque Psoriasis: A Cross-Sectional Study.Extrahepatic Manifestations of Nonalcoholic Fatty Liver DiseasePsoriasis severity and the prevalence of major medical comorbidity: a population-based studyRelationship between psoriasis and non-alcoholic fatty liver disease.The therapeutic potential of TNF-alpha antagonists for skin psoriasis comorbidities.Psoriasis and non-alcoholic fatty liver disease.Adipokines and psoriasis.Obesity and psoriasis: body weight and body mass index influence the response to biological treatment.Alcohol, psoriasis, liver disease, and anti-psoriasis drugs.The effects of alcohol on the metabolism and toxicology of anti-psoriasis drugs.Psoriasis: rationale for targeting interleukin-17.Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis.Cardiovascular aspects of psoriasis: an updated review.Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies.Markers of systemic inflammation in psoriasis: a systematic review and meta-analysis.Does treatment of psoriasis reduce the risk of cardiovascular disease?Methotrexate and liver fibrosis in people with psoriasis: a systematic review of observational studies.A review of methotrexate-associated hepatotoxicity.Noninvasive Testing for Nonalcoholic Steatohepatitis and Hepatic Fibrosis in Patients With Psoriasis Receiving Long-term Methotrexate Sodium Therapy.Pediatric Psoriasis Comorbidity Screening Guidelines.Diagnosing liver fibrosis: a narrative review of current literature for dermatologists.Enhanced liver fibrosis test in patients with psoriasis, psoriatic arthritis and rheumatoid arthritis: a cross-sectional comparison with procollagen-3 N-terminal peptide (P3NP).Metabolic syndrome in Moroccan patients with psoriasis.
P2860
Q26745789-D2FD61C5-E23C-4D09-82BF-3F372D03630FQ26767276-D0DD8F08-B841-4A97-97B5-CE9ADD3EB08EQ26998754-A3F20485-B363-421D-83DB-00DFD7ACD2AEQ28079077-E8AC2E08-3CC9-4708-B81F-AD4ADD2C4435Q28087039-95132EC5-AC62-4331-9EDC-7A79B29B01D7Q28088340-5AD522B5-8424-47FD-B603-0AE9724CAA9CQ30238648-DBA4A05E-3A99-4DAA-BAF9-86F168068737Q30249013-E8902AF0-00E7-46CC-B7A5-BC56A91BC8C3Q33785074-8AD69757-717F-4C1C-A0D5-3401881D0308Q34130103-321DAA7B-ACC8-4948-B8FB-4CC6726F53B6Q34418506-10E4F45D-A261-4EBF-BC52-660D18A7B639Q34753522-B1C88FCD-E9DD-49F7-B0E4-8D9C11DD7F2FQ35109287-34FCB098-B62B-4B6D-ADBC-E70120CC99D9Q35237307-651220D7-B28B-42F8-9CCF-35E249DFEE03Q35308947-FD522C79-F209-4E95-9ABD-E86C82BC6221Q35444953-5DDB45D8-1582-4702-BED9-A9407A7BAC71Q36063026-9E25F37A-1C2D-4D9B-9329-33C278BE706DQ36252677-772B2EF3-C63B-4211-83C0-DC5E3A3CB7C8Q36921610-38C11DD2-1ED5-4C24-AFC0-B0BE7E714C00Q37239394-59699A02-AD85-4D27-B754-A11F8822D4FBQ37553636-3F56AFC5-7BC6-4B45-B124-E88FD5D6B203Q37766229-F663DC1F-E793-436B-9A68-538F9BE179C5Q37788777-65657A25-6808-4AF3-B489-F7ADE3A5D233Q37831388-63229223-8E61-4ACF-A513-D38164079373Q37865060-24759A54-0AA4-4595-9B1C-6C81645A926CQ37946497-A27EBDB6-834F-49DF-9F2B-E37712B19519Q38010769-F4840CB3-01D1-4CAE-97D6-F9DD609ABFB8Q38020227-467689D6-D401-4169-9AFE-C76A1EA3B324Q38058361-6016AD0E-C4A5-44CA-B24B-6F50716EA745Q38076496-9CE2FD0C-71AE-461A-8ED9-58FC44254AFCQ38083089-9AF1CA09-0EE2-4304-BF1A-B02B908E0A6EQ38095512-E9D55DF1-A271-4695-B45B-9E309C6F3BAEQ38178202-688F6CEF-80F9-4FDB-950F-0F9F95F7163AQ38194199-84629C2A-A9C8-4A05-A91D-478DCA37BF3EQ38241492-4F271B24-4965-4EB9-A917-B5F251496FD2Q38612446-8BF7F8B1-8875-4CDA-8EA4-AFE20E8E974FQ38682771-B512FD7F-5BDF-4B8B-AA55-4CAA5390A6A9Q38780434-4714C20F-1CEC-46FE-8E19-D7DC7B45BF3BQ39124718-C11C585C-4549-48C0-AC85-F31497C15CBDQ39248840-6D25A132-2344-4DBC-9211-818A6B1315CC
P2860
Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis.
@en
Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis.
@nl
type
label
Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis.
@en
Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis.
@nl
prefLabel
Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis.
@en
Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis.
@nl
P2093
P1476
Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis.
@en
P2093
Giacomo Zoppini
Giampiero Girolomoni
Giovanni Targher
Paolo Gisondi
P304
P356
10.1016/J.JHEP.2009.04.020
P577
2009-05-27T00:00:00Z